Synbio Pharmaceuticals ＜4582＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 7th. Net sales decreased 61.3% from the same period last year to 597 million yen, operating loss was 806 million yen (profit of 51 million yen in the same period last year), ordinary loss was 727 million yen (profit of 0.48 billion yen), and quarterly net loss attributable to parent company shareholders was 777 million yen (same profit of 0.4 billion yen).

Currently, RI (rapid intravenous infusion) administration that shortens the administration time of treaxin (R) intravenous solution 100 mg/4 mL [RTD (ready-to-dose) preparation] to 10 minutes has been approved. Compared to conventional freeze-dried formulations (FD formulations), RTD formulations can shorten the time required for complicated manual dissolution work, and since administration time is drastically shortened from the conventional 60 minutes to 10 minutes by RI administration, the burden on patients and health care workers can be greatly reduced. Also, since the infusion amount is 50 mL, which is drastically reduced from the conventional 250 mL, the amount of salt can also be reduced. As of the end of 2024/3, over 90% of medical facilities are receiving RI administration to patients. Regarding sales activities, prescriptions of bendamustine continue due to concerns that it may cause the spread or severity of infections during or after treatment with bendamustine. Also, due to the effects of drug price revisions, sales declined due to the effects that seem to be narrowing down hospital inventory is progressing. Sales expenses and general administrative expenses were recorded as research and development expenses of 691 million yen (up 25.75% from the same period last year), and the total of other sales expenses and general administrative expenses was 1,277 billion yen (up 7.2% from the same period last year).

Regarding research and development activities, the business development of injectables and oral agents of the antiviral drug SyBv-1901 (generic name: brincidofovir ＜brincidofovir ＞ “BCV”) introduced from Chimerix Inc. (Chimerix Inc.) with an eye on global expansion has a wide range of activity against double-stranded DNA viruses (dsDNA viruses), so we are proceeding with joint research facilities with leading domestic and overseas research facilities in specialized fields. It is planned to examine and conduct global clinical trials based on scientific knowledge, which is research results.

Revisions to earnings forecasts for the full fiscal year ending 2024/12 were announced on the same day. Sales are down 53.1% from the previous fiscal year (down 28.0% from the previous forecast) to 2,623 billion yen, operating loss is 3.702 billion yen (down 30.5% from the same period), ordinary loss is 3.524 billion yen (22.9% decrease from the same period), and net loss attributable to the parent company is 36.28 billion yen (down 26.4% from the same period).